Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Atenolol Market size was over USD 12.23 billion in 2024 and is anticipated to cross USD 24.53 billion by 2037, witnessing more than 5.5% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of atenolol is assessed at USD 13.33 billion.
The growth of the market can be attributed to the worldwide expanding ratio of hypertension among people, coupled with the surging awareness regarding the concerned complexities of hypertension. As per the World Health Organization (WHO) data, an estimated 1.28 billion persons aged 30-79 years have hypertension across the globe, with the majority two-thirds residing in low- and middle-income nations. Further, the dynamically growing demand for antihypertensive drugs throughout the world is also projected to skyrocket the growth of the global atenolol market over the forecast period.
In addition to these, factors that are believed to fuel the market growth of atenolol include the significant rise in the aged population throughout the world, as aged people are more prone to have disorders comprising hypertension, cardiac diseases, diabetes, and so on. As stated by the World Health Organization, the global population of persons aged 60 and above is projected to surge from 1 billion in 2020 to 1.4 billion by 2030. Moreover, the global population of people aged 60 and above is expected to augment to 2.1 billion by 2050. Further, poor lifestyle along with poor dietary habits among people is also estimated to fuel the market growth in the coming years.
Atenolol Sector: Growth Drivers and Challenges
Growth Drivers
- Growing Prevalence of Angina Experiences - Angina is a type of chest pain that occurs by a decrease in blood flow to the heart. It is mainly caused by an accumulation of fatty deposits in the arteries supplying blood to the heart muscles. In such a condition, the heart beats faster and a person feels a sharp pain and pressure in his/her chest. It is an early sign of heart disorders. Atenolol belongs to a class of drugs referred to as beta blockers. Beta-blockers decrease the oxygen demand of the heart and lower the occurrence of angina attacks by reducing heart rate. Hence, the increasing prevalence of angina attacks is estimated to expand market growth further over the projected time frame. For instance, in the United States, each year angina affects more than 9 million people.
- Expansion in Sedentary Lifestyle - Physical inactivity can have major adverse health effects. An inactive lifestyle raises the risk of all causes that result in death and doubles the chance of a variety of conditions such as cardiovascular disease, diabetes, obesity, anxiety, and so on. Therefore, an increase in sedentary lifestyles is also projected to drive the growth of the atenolol market in the coming years. As reported by the World Health Organization, 27% of adults and more than 80% of adolescents globally fail to comply with the recommended physical activity ratio.
- Increasing Prevalence of Arrhythmia - Any issue with a person's heartbeat rate or rhythm is referred to as an "arrhythmia." Electrical waves that are too fast, too slow, or chaotic during an arrhythmia can cause an irregular heartbeat. The heart cannot properly pump blood when it is not beating appropriately. The lungs, brain, and all the other organs are unable to function properly and may get damaged. Atenolol helps in this situation by lowering your heart rate, which makes it easier for your heart to circulate blood throughout the organs. Thus, the rising prevalence of arrhythmia is also estimated to boost the market growth of atenolol over the forecast period. As per an estimation, Arrhythmia is anticipated to affect approximately 1.7% to 6% of the overall population in the United States.
- Rise in Poor Dietary Habits - According to a new worldwide study conducted in 2021, approximately 50% of the global population suffers from poor dietary habits, which has negative consequences for people.
- Rising Cases of Cardiovascular Disorders – Based on the World Health Organization figures, cardiovascular diseases are the most prevalent cause of death throughout the world, claiming the lives of an estimated 17.9 million people annually.
Challenges
- Associated Side Effects of Atenolol – Though atenolol helps to tackle several kinds of hypertension issues still numerous side effects are associated with the use of atenolol comprising feeling sleepiness, dizziness, nausea, hypotension, blurred vision, bloody urination, and so on. Hence, this factor is anticipated to dampen the growth of the market in the coming years.
- Availability of Diuretics and Other Drugs
- Risk of Interaction with Other Drugs
Atenolol Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.5% |
|
Base Year Market Size (2024) |
USD 12.23 billion |
|
Forecast Year Market Size (2037) |
USD 24.53 billion |
|
Regional Scope |
|
Atenolol Segmentation
Application (Hypertension, Angina, Arrhythmia)
The global atenolol market is segmented and analyzed for demand and supply by application into hypertension, angina, arrhythmia, and others. Out of these four types of segments, the hypertension segment is estimated to gain the largest market share of about 55% in the year 2037. The growth of the segment can be attributed to the increasing prevalence of hypertension throughout the world, coupled with the expanding demand and consumption of antihypertensive drugs across the globe. For instance, the worldwide revenue of antihypertensive drugs is anticipated to boost by around USD 24 billion by the end of 2023. In addition to this, the rising awareness in people regarding hypertension is also estimated to fuel the segment growth in the coming years.
Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies)
The global atenolol market is also segmented and analyzed for demand and supply by distribution channel into hospital pharmacies, drug stores, online pharmacies, and others. Amongst these four segments, the hospital pharmacies segment is expected to garner a significant share of around 49% in the year 2037. The growth of the segment can be attributed to the rising patient pool of hypertension, arrhythmia, angina, and so on in hospitals to get better treatment, coupled with the surging ratio of hospitals throughout the world. In addition to this, the rise in cardiovascular disorder is also anticipated to accelerate segment growth in the coming years. On the other hand, the online pharmacies segment is projected to witness an impressive CAGR during the forecast period on the back of the rising awareness of these online platforms amongst users worldwide. In addition to this, the expanding penetration of the internet throughout the world is another major factor estimated to drive segment growth across the globe in the coming years.
Our in-depth analysis of the global market includes the following segments:
|
By Form |
|
|
    By Dosage Type |
|
|
    By Application |
|
|
   By Distribution Channel |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Atenolol Industry - Regional Synopsis
North American Market Forecast
North America industry is set to hold largest revenue share of 40% by 2037. The growth of the market can be attributed majorly to the increasing prevalence of cardiac diseases, along with the rising frequency of hypertension in the region. For instance, approximately 1 in every 18 people, or 5% of the U.S. population has arrhythmia. Furthermore, as per the statistics by the Centers for Disease Control and Prevention, in the U.S., 116 million individuals have hypertension, and in 2019, 0.5 million deaths were caused directly or indirectly by hypertension. In addition to this, the increasing availability of advanced treatment and medications, followed by the surge in healthcare expenditure is also projected to drive the growth of the atenolol market further during the projected time frame in the region.
APAC Market Statistics
The Asia Pacific atenolol market is estimated to be the second largest, registering a share of about 28% by the end of 2037. The growth of the market can be attributed majorly to the rising burden of hypertension, coupled with the surge in population, and changing lifestyle of people in the region. Besides this, the growing awareness in people regarding the use of hypertension drugs is also a significant factor anticipated to drive market growth in the region during the forecast period. In addition to this, an increase in inappropriate diet habits, coupled with the surge in fast food consumption is also estimated to drive market growth in the APAC region during the forecast period.
Europe Market Forecast
Further, the market in Europe, amongst the market in all the other regions, is projected to hold a noteworthy share of about 17% by the end of 2037. The growth of the market can be attributed majorly, as the region has witnessed a sharp hike in the cases of cardiovascular diseases. For instance, every year, more than 1.6 million deaths in the European Union and 4 million deaths in Europe are attributed to cardiovascular diseases. Moreover, efficient and inexpensive healthcare facilities in European countries are estimated to support the growth of the market. In addition to this, the surge in the life science sector is also estimated to drive the growth of the atenolol market in the European region.
Companies Dominating the Atenolol Landscape
- Intas Pharmaceuticals Limited
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- Sysmex Corporation
- Zydus Pharmaceuticals (USA) Inc.
- Ipca Laboratories Limited
- Unichem Laboratories Limited
- AstraZeneca PLC
Recent Developments
-
Unichem Laboratories Limited obtained ANDA authorization from the United States Food and Drug Administration (USFDA) for its Atenolol and Chlorthalidone Tablets, USP 50 mg/25 mg and 100 mg/25 mg to be sold as a generic version of Alvogen Malta Operations Ltd's TENORETIC (atenolol and chlorthalidone) Tablets.
-
AstraZeneca PLC has approved the sale of the worldwide commercial rights Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril), and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination) to Atnahs Pharma. This deal has eliminated the already sold rights in the United States and India, as well as the rights in Japan, which will be kept by AstraZeneca.
- Report ID: 4076
- Published Date: Dec 20, 2024
- Report Format: PDF, PPT
Have specific data needs or budget constraints?
Reach out to us for a customized quote or to learn more about our special pricing
for startups and universities
Frequently Asked Questions (FAQ)
Atenolol Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
